163 related articles for article (PubMed ID: 23213231)
1. Neuregulin 1-HER axis as a key mediator of hyperglycemic memory effects in breast cancer.
Park J; Sarode VR; Euhus D; Kittler R; Scherer PE
Proc Natl Acad Sci U S A; 2012 Dec; 109(51):21058-63. PubMed ID: 23213231
[TBL] [Abstract][Full Text] [Related]
2. Neuregulin-1 induces cancer stem cell characteristics in breast cancer cell lines.
Jeong H; Kim J; Lee Y; Seo JH; Hong SR; Kim A
Oncol Rep; 2014 Sep; 32(3):1218-24. PubMed ID: 25018110
[TBL] [Abstract][Full Text] [Related]
3. HER3 is required for the maintenance of neuregulin-dependent and -independent attributes of malignant progression in prostate cancer cells.
Soler M; Mancini F; Meca-Cortés O; Sánchez-Cid L; Rubio N; López-Fernández S; Lozano JJ; Blanco J; Fernández PL; Thomson TM
Int J Cancer; 2009 Dec; 125(11):2565-75. PubMed ID: 19530240
[TBL] [Abstract][Full Text] [Related]
4. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin.
Garner AP; Bialucha CU; Sprague ER; Garrett JT; Sheng Q; Li S; Sineshchekova O; Saxena P; Sutton CR; Chen D; Chen Y; Wang H; Liang J; Das R; Mosher R; Gu J; Huang A; Haubst N; Zehetmeier C; Haberl M; Elis W; Kunz C; Heidt AB; Herlihy K; Murtie J; Schuller A; Arteaga CL; Sellers WR; Ettenberg SA
Cancer Res; 2013 Oct; 73(19):6024-35. PubMed ID: 23928993
[TBL] [Abstract][Full Text] [Related]
5. Neuregulin autocrine signaling promotes self-renewal of breast tumor-initiating cells by triggering HER2/HER3 activation.
Lee CY; Lin Y; Bratman SV; Feng W; Kuo AH; Scheeren FA; Engreitz JM; Varma S; West RB; Diehn M
Cancer Res; 2014 Jan; 74(1):341-52. PubMed ID: 24177178
[TBL] [Abstract][Full Text] [Related]
6. Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer.
Ogier C; Colombo PE; Bousquet C; Canterel-Thouennon L; Sicard P; Garambois V; Thomas G; Gaborit N; Jarlier M; Pirot N; Pugnière M; Vie N; Gongora C; Martineau P; Robert B; Pèlegrin A; Chardès T; Larbouret C
Cancer Lett; 2018 Sep; 432():227-236. PubMed ID: 29935372
[TBL] [Abstract][Full Text] [Related]
7. Direct binding of the EGF-like domain of neuregulin-1 to integrins ({alpha}v{beta}3 and {alpha}6{beta}4) is involved in neuregulin-1/ErbB signaling.
Ieguchi K; Fujita M; Ma Z; Davari P; Taniguchi Y; Sekiguchi K; Wang B; Takada YK; Takada Y
J Biol Chem; 2010 Oct; 285(41):31388-98. PubMed ID: 20682778
[TBL] [Abstract][Full Text] [Related]
8. Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells.
Kang JC; Poovassery JS; Bansal P; You S; Manjarres IM; Ober RJ; Ward ES
MAbs; 2014; 6(2):340-53. PubMed ID: 24492289
[TBL] [Abstract][Full Text] [Related]
9. The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic
Odintsov I; Lui AJW; Sisso WJ; Gladstone E; Liu Z; Delasos L; Kurth RI; Sisso EM; Vojnic M; Khodos I; Mattar MS; de Stanchina E; Leland SM; Ladanyi M; Somwar R
Clin Cancer Res; 2021 Jun; 27(11):3154-3166. PubMed ID: 33824166
[TBL] [Abstract][Full Text] [Related]
10. The E3 ubiquitin ligase NEDD4 negatively regulates HER3/ErbB3 level and signaling.
Huang Z; Choi BK; Mujoo K; Fan X; Fa M; Mukherjee S; Owiti N; Zhang N; An Z
Oncogene; 2015 Feb; 34(9):1105-15. PubMed ID: 24662824
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic regulation of Neuregulin 1 promotes breast cancer progression associated to hyperglycemia.
Lee C; Kim M; Park C; Jo W; Seo JK; Kim S; Oh J; Kim CS; Ryu HS; Lee KH; Park J
Nat Commun; 2023 Jan; 14(1):439. PubMed ID: 36707514
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling.
De Boeck A; Pauwels P; Hensen K; Rummens JL; Westbroek W; Hendrix A; Maynard D; Denys H; Lambein K; Braems G; Gespach C; Bracke M; De Wever O
Gut; 2013 Apr; 62(4):550-60. PubMed ID: 22535374
[TBL] [Abstract][Full Text] [Related]
13. Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines.
Momeny M; Saunus JM; Marturana F; McCart Reed AE; Black D; Sala G; Iacobelli S; Holland JD; Yu D; Da Silva L; Simpson PT; Khanna KK; Chenevix-Trench G; Lakhani SR
Oncotarget; 2015 Feb; 6(6):3932-46. PubMed ID: 25668816
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity.
Lindberg K; Helguero LA; Omoto Y; Gustafsson JÅ; Haldosén LA
Breast Cancer Res; 2011 Apr; 13(2):R43. PubMed ID: 21492444
[TBL] [Abstract][Full Text] [Related]
15. The neuregulin-I/ErbB signaling system in development and disease.
Britsch S
Adv Anat Embryol Cell Biol; 2007; 190():1-65. PubMed ID: 17432114
[TBL] [Abstract][Full Text] [Related]
16. Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers.
Flågeng MH; Larionov A; Geisler J; Knappskog S; Prestvik WS; Bjørkøy G; Lilleng PK; Dixon JM; Miller WR; Lønning PE; Mellgren G
J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt B):228-235. PubMed ID: 27343990
[TBL] [Abstract][Full Text] [Related]
17. ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma.
Capparelli C; Purwin TJ; Heilman SA; Chervoneva I; McCue PA; Berger AC; Davies MA; Gershenwald JE; Krepler C; Aplin AE
Cancer Res; 2018 Oct; 78(19):5680-5693. PubMed ID: 30115691
[TBL] [Abstract][Full Text] [Related]
18. Constitutive activation of neuregulin/ERBB3 signaling pathway in clear cell sarcoma of soft tissue.
Schaefer KL; Brachwitz K; Braun Y; Diallo R; Wai DH; Zahn S; Schneider DT; Kuhnen C; Vollmann A; Brockhoff G; Gabbert HE; Poremba C
Neoplasia; 2006 Jul; 8(7):613-22. PubMed ID: 16867224
[TBL] [Abstract][Full Text] [Related]
19. Diabetes as a prognostic factor in HER-2 positive breast cancer patients treated with targeted therapy.
Lee A; Jo S; Lee C; Shin HH; Kim TH; Ahn KJ; Park SK; Cho H; Yoon HK; Kim WG; Park J; Choi Y
Breast Cancer; 2019 Sep; 26(5):672-680. PubMed ID: 30927244
[TBL] [Abstract][Full Text] [Related]
20. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]